BC Week In Review | Sep 16, 2002
Company News

Hybridon, Micrologix, OriGenix deal

MGXIF acquired an exclusive, worldwide license to HYBN’s IP covering a number of antisense oligonucleotides targeting human papillomavirus (HPV). MGI also acquired non-exclusive rights to a portfolio of HYBN antisense chemistries. Separately, MBI acquired rights...
BC Extra | Sep 12, 2002
Company News

Micrologix, Hybridon HPV deal

Micrologix (TSE:MBI; MGXIF) acquired an exclusive, worldwide license to HYBN's IP covering a number of antisense oligonucleotides targeting human papillomavirus (HPV). MGI also acquired non-exclusive rights to a portfolio of HYBN antisense chemistries. Separately, MBI...
BC Week In Review | Sep 10, 2001
Clinical News

ORI-1001 topical gel: Began Phase I testing

Origenix Technologies Inc., Montreal, Quebec   Product: ORI-1001 topical gel   Business: Infectious diseases   Therapeutic category: Antisense   Target: E1 region of the human papillomavirus (HPV)   Description: Oligonucleotide inhibitor of E1 region of...
BC Week In Review | Mar 26, 2001
Company News

OriGenix board of directors update

Origenix Technologies Inc., Montreal, Quebec   Business: Infectious diseases   Appointed: Michael Atkin, president and CEO of Aegera Therapeutics Inc. ; and Barry Markowsky, head of business development at GlaxoSmithKline (Canada)  ...
BC Week In Review | Mar 26, 2001
Company News

OriGenix management update

Origenix Technologies Inc., Montreal, Quebec   Business: Infectious diseases   Hired: Anthony Payne as EVP of finance and business development, formerly an industry consultant  ...
BC Week In Review | Feb 1, 1999
Company News

OriGenix management update

(Financing, B15) OriGenix Technologies Inc., Montreal, Quebec   Business: Infectious diseases   Hired: Douglas Jensen as president and CEO, formerly VP of administration and corporate development at Hybridon Inc.  ...
Items per page:
1 - 6 of 6
BC Week In Review | Sep 16, 2002
Company News

Hybridon, Micrologix, OriGenix deal

MGXIF acquired an exclusive, worldwide license to HYBN’s IP covering a number of antisense oligonucleotides targeting human papillomavirus (HPV). MGI also acquired non-exclusive rights to a portfolio of HYBN antisense chemistries. Separately, MBI acquired rights...
BC Extra | Sep 12, 2002
Company News

Micrologix, Hybridon HPV deal

Micrologix (TSE:MBI; MGXIF) acquired an exclusive, worldwide license to HYBN's IP covering a number of antisense oligonucleotides targeting human papillomavirus (HPV). MGI also acquired non-exclusive rights to a portfolio of HYBN antisense chemistries. Separately, MBI...
BC Week In Review | Sep 10, 2001
Clinical News

ORI-1001 topical gel: Began Phase I testing

Origenix Technologies Inc., Montreal, Quebec   Product: ORI-1001 topical gel   Business: Infectious diseases   Therapeutic category: Antisense   Target: E1 region of the human papillomavirus (HPV)   Description: Oligonucleotide inhibitor of E1 region of...
BC Week In Review | Mar 26, 2001
Company News

OriGenix board of directors update

Origenix Technologies Inc., Montreal, Quebec   Business: Infectious diseases   Appointed: Michael Atkin, president and CEO of Aegera Therapeutics Inc. ; and Barry Markowsky, head of business development at GlaxoSmithKline (Canada)  ...
BC Week In Review | Mar 26, 2001
Company News

OriGenix management update

Origenix Technologies Inc., Montreal, Quebec   Business: Infectious diseases   Hired: Anthony Payne as EVP of finance and business development, formerly an industry consultant  ...
BC Week In Review | Feb 1, 1999
Company News

OriGenix management update

(Financing, B15) OriGenix Technologies Inc., Montreal, Quebec   Business: Infectious diseases   Hired: Douglas Jensen as president and CEO, formerly VP of administration and corporate development at Hybridon Inc.  ...
Items per page:
1 - 6 of 6